and Human Services (HHS)
EXPIRED
COHORT STUDIES IN CANCER EPIDEMIOLOGY
RELEASE DATE: October 20, 2003
PA NUMBER: PAR-04-011 (see addenda NOT-CA-04-021 and NOT-CA-04-001)
EXPIRATION DATE: November 2, 2005, unless reissued.
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATIONS:
National Institutes of Health (NIH)
(http://www.nih.gov)
COMPONENTS OF PARTICIPATING ORGANIZATIONS:
National Cancer Institute (NCI)
(http://www.nci.nih.gov)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.399
LETTER OF INTENT RECEIPT DATE: May 1, 2004; January 2, 2005; September 1, 2005
APPLICATION RECEIPT DATES FOR NEW APPLICATIONS: June 1, 2004; February 1, 2005;
October 1, 2005
APPLICATION RECEIPT DATES FOR COMPETING CONTINUATIONS (TYPE 2), COMPETITIVE
SUPPLEMENTS, AND REVISED APPLICATIONS: July 1, 2004; March 1, 2005;
November 1, 2005
This Program Announcement (PA) replaces PAS-02-009, which was published in
the NIH Guide on October 11, 2001.
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of the PA
o Research Objectives
o Mechanism of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Receipt and Review Schedule
o Required Federal Citations
PURPOSE OF THIS PA
The Division of Cancer Control and Population Sciences (DCCPS) of the
National Cancer Institute (NCI) announces special receipt dates for R01 grant
applications from investigators intending to initiate, competitively
supplement, or competitively renew population-based epidemiologic or
survivorship cohort studies of human cancers. The purpose of the Program
Announcement (PA) is to coordinate the submission, review, and funding of
population-based epidemiologic or survivorship cohort studies, and covers
applications characterized by their cohort design and direct costs of
$500,000 or more in any one study year. This PA represents a continuation of
previous NCI policy, in that the NCI does not accept unsolicited applications
at these budget levels for population-based cohorts. All usual NIH grants
policies apply to these awards.
RESEARCH OBJECTIVES
Prospective population-based cohort studies are one of the mainstays of
epidemiologic inquiry, and have the clear advantage over cross-sectional and
case-control study designs of unbiased assessment of multiple pre-diagnostic
exposures and the ability to assess multiple outcomes. In the cohort design,
information on the study factor is known for all subjects at the beginning of
the follow-up period, and they are followed over time to determine who among
them develop the disease(s) of interest. Therefore, the study factor of
interest, or exposure, is observed and measured before the disease is
detected, making it likely that the study factor is related to disease
development (i.e., is a risk factor) instead of being part of the disease
process. Also, it is much less likely that the presence or absence of the
study factor of interest can differentially influence selection of study
participants on the basis of disease outcome status. Once a population-based
cohort is established, and data and bio-specimens become available, it
typically becomes an attractive infrastructure for additions or supplements
to address new areas of scientific investigation. Often the cohort is used
to study other diseases in addition to cancer.
However, these types of population-based cohort studies are usually
substantially more time-consuming and expensive than most cross-sectional and
case-control approaches, and are usually less suitable for study of more
uncommon outcomes unless very large numbers of subjects are followed. Also,
because study factor information must be observed at the outset of the study,
a cohort study design limits opportunities for generating new etiologic
hypotheses requiring information on other, unanticipated exposures.
Rigorous scientific inquiry in gene-gene and gene-environment interactions
has raised the awareness of the role of prospective population-based cohorts,
with a concomitant increase in number, scale, and costs of the research
grants. Cohort studies have been tremendously useful tools, particularly in
assessment of exposures and capture of multiple outcomes. However, cohort
research proposals are frequently submitted without full appreciation of the
opportunities for research nested within existing cohorts. Most new cohorts
require the passage of years before accumulation of enough endpoints to
analyze. Existing cohorts include people who are well characterized, and
likely already experiencing the impact of environmental exposures. Issues of
key interest to the NCI with regard to these resources include continuity of
funding, balance of important cohort characteristics, quality of design,
rigor in exposure assessment, response and follow-up rates, bio-specimen
collection and storage, bioinformatics, availability of bio-specimen
resources to outside qualified investigators, and willingness to collaborate
with other investigators in the establishment of research consortia.
Potential applicants are encouraged to learn more about extramurally funded,
large, population-based epidemiologic and survivorship cohort studies at the
NCI at the following website:
http://epi.grants.cancer.gov/ResPort/cohorts.html.
Coordination of research infrastructure in the arena of population-based
cohorts may be expected to yield new and expanded opportunities for study, as
the biomedical resources are made available to outside investigators. These
large databases will afford the opportunity to study hypotheses that would be
underpowered in smaller studies. This is especially true in the study of
gene-environment and gene-gene interactions, in which large numbers of study
participants followed in a standardized fashion are required. In addition,
NCI coordination of population-based epidemiologic and survivorship cohorts
will make it possible to identify gaps, whether in special populations,
special cancers of high interest, or other special outcomes.
Applications pursuant to this PA are limited to population-based
epidemiologic and survivorship cohort studies of human cancers.
This PA covers population-based epidemiologic and survivorship cohort
applications requesting $500,000 or more in direct costs (excluding third-
party facility and administrative, formerly indirect, costs) in any one
project year. Potential applicants are encouraged to become familiar with
existing resources at the address listed above,
http://epi.grants.cancer.gov/ResPort/cohorts.html.
Examples of applications that MUST be submitted under this solicitation
include the following:
o applications for new population-based epidemiologic cohort studies of human
cancers requesting $500,000 direct costs or more in any one project year
o applications for new survivorship cohorts of human cancers requesting
$500,000 direct costs or more in any one project year
o applications for competitive supplements to an NCI-funded population-based
epidemiologic or survivorship cohort study that would result in such study
costing $500,000 direct costs or more in any one project year
o applications for competitive renewal (Type 2) of an NCI-funded population-
based epidemiologic or survivorship cohort study requesting $500,000 direct
costs or more in any one project year
This solicitation specifically EXCLUDES the following:
o applications for new and existing epidemiologic cohort studies of HIV-
related malignancies, which will continue to be submitted and reviewed under
existing NIH guidelines for AIDS-related research and under PA-03-024,
Molecular Epidemiology of Cancers Associated with Acquired Immunodeficiency
o applications for new and existing epidemiologic cohort studies of
individuals at high genetic risk for cancer
o applications for new and existing intervention studies, including
randomized controlled trials
o administrative supplements, such as those resulting from unexpected loss of
equipment or increase in costs of a test
MECHANISMS OF SUPPORT
This PA will use the NIH investigator-initiated research project grants (R01)
award mechanism(s). As an applicant, you will be solely responsible for
planning, directing, and executing the proposed project. The total project
period for an application submitted in response to the PA may not exceed FIVE
years. The earliest anticipated award date is April 2005.
Revisions of unsuccessful applications submitted under this PA will ONLY be
accepted in response to future reissuances of this PA. The next submission
opportunity for competing continuations, supplements, and revisions is July
1, 2004 . Revised versions of unsuccessful applications may NOT be submitted
under other mechanisms, including submission of revised applications to the
NIH Center for Scientific Review (CSR) for standard R01 receipt dates not
specified as submission opportunities in this PA. NCI will not accept
applications, including revisions, for population-based epidemiologic and
survivorship cohorts costing $500,000 or more direct costs in any one study
year that are not submitted in response to this PAR. Though the size of award
may vary with the scope of research proposed, applications must stay within
the NCI budgetary guidelines for R01 investigator-initiated competing
projects. Application for competitive renewal of existing cohorts (Type 2)
will be limited to a 20 percent increase over the last non-competing (Type 5)
year. In cases where the last non-competing year budget was substantially
lower than other previous years, and if the nature of the new research
requires budget increases for one or more years above the 20 percent rule for
the last non-competing year, applicants may cite the average yearly direct
cost as a base for the new cap. Applicants interested in this option are
required to contact the NCI program director for the currently funded grant
before submitting applications. Requests for exceptions to the 20 percent
cap on Type 2 applications will NOT be granted. Further information on NCI
policy in this area may be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-01-019.html. Letters of
Intent are strongly recommended, and are due May 1, 2004 (for the first
receipt date), January 2, 2005 (for the second receipt date), or September 1,
2005 (for the third receipt date).
This PA uses just-in-time concepts. It also uses the non-modular budgeting
formats (see http://grants.nih.gov/grants/funding/modular/modular.htm). This
program does not require cost sharing as defined in the current NIH Grants
Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2001/part_i_1.htm.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign institutions/organizations
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
SPECIAL REQUIREMENTS
Effective with the October 1, 2003, receipt date for NIH applications, NIH
expects timely release and sharing of final research data for use by other
researchers. Grant applications must include a plan for data sharing, or
state why data sharing is not possible. Data sharing plans must be discussed
with NIH Institute/Center staff for all applications submitted under this PA.
Information on data sharing must be included in relevant sections of the
grant application, including a data sharing plan at the end of the Research
Plan, Budget and Budget Justification if asking for funds, and in Background
and Significance sections if creating an important scientific resource.
Institute/Center program staff will be responsible for assessing the
appropriateness and adequacy of the data sharing plan, and program concerns
must be resolved prior to making an award. Reviewers will review the data
sharing plan, but it will not be included in determinations of the scientific
merit or priority score for an application. Further information on the NIH
data sharing requirements may be found at
http://grants.nih.gov/grants/policy/data_sharing.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, financial or grants management, and review
issues:
o Direct your questions about scientific/research issues to:
Sandra L. Melnick, Dr.P.H.
Division of Cancer Control and Population Sciences
National Cancer Institute
Executive Plaza North, Room 5100, MSC 7324
Bethesda, MD 20892-7324
Telephone: (301) 435-4914
FAX: (301) 402-4279
Email: [email protected]
o Direct your inquiries regarding peer review issues to:
Denise Wiesch, Ph.D.
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 3150, MSC 7770
Bethesda, MD 20892-7770
Bethesda, MD 20817 (for express/courier service)
Telephone: (301) 435-0684
Fax: (301) 480-3962
Email: [email protected]
o Direct your questions about financial or grants management matters to:
Crystal Wolfrey
Division of Extramural Activities
National Cancer Institute
Executive Plaza South, Room 234, MSC 7150
Bethesda, MD 20892-7150
Telephone: (301) 496-8634
FAX: (301) 496-8601
Email: [email protected]
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this PA
Although a letter of intent is not required, is strongly recommended, not
binding, and does not enter into the review of a subsequent application, the
information that it includes allows NCI staff to estimate the potential
review workload and plan the review.
The letter of intent is to be sent by the date listed at the beginning of
this document. The letter of intent should be sent to:
Sandra L. Melnick, Dr.P.H.
Division of Cancer Control and Population Sciences
National Cancer Institute
Executive Plaza North, Room 5100, MSC 7324
Bethesda, MD 20892-7324
Telephone: (301) 435-4914
FAX: (301) 402-4279
Email: [email protected]
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the
Universal Identifier when applying for Federal grants or cooperative
agreements. The DUNS number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of the PHS 398 form. The PHS
398 document is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: [email protected].
The title, Cohort Studies in Cancer Epidemiology, and the number of the
program announcement (PAR-04-011) must be typed on line 2 of the face page of
the application form and the YES box must be marked.
APPLICATION RECEIPT DATES: Applications submitted in response to this
program announcement will be accepted by the receipt dates listed on the
first page of this program announcement ONLY.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and five signed photocopies in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
APPLICATION PROCESSING: Applications must be mailed on or before the receipt
dates described at
http://grants.nih.gov/grants/funding/submissionschedule.htm. The CSR will
not accept any application in response to this PA that is essentially the
same as one currently pending initial review unless the applicant withdraws
the pending application. The CSR will not accept any application that is
essentially the same as one already reviewed. This does not preclude the
submission of a substantial revision of an unfunded version of an application
already reviewed, but such application must include an Introduction
addressing the previous critique.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
PEER REVIEW PROCESS
Applications submitted for this PA will be assigned on the basis of
established PHS referral guidelines. Appropriate scientific review groups
convened in accordance with the standard NIH peer review procedures
(http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific
and technical merit.
As part of the initial merit review, all applications will:
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications under
review, will be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the National Cancer Advisory Board.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to evaluate the application in
order to judge the likelihood that the proposed research will have a
substantial impact on the pursuit of these goals. The scientific review
group will address and consider each of these criteria in assigning the
application’s overall score, weighting them as appropriate for each
application.
o Significance
o Approach
o Innovation
o Investigator
o Environment
The application does not need to be strong in all categories to be judged
likely to have major scientific impact and thus deserve a high priority
score. For example, an investigator may propose to carry out important work
that by its nature is not innovative but is essential to move a field
forward.
SIGNIFICANCE: Does this study address an important problem? If the aims of
the application are achieved, how will scientific knowledge be advanced? What
will be the effect of these studies on the concepts or methods that drive
this field?
APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
INNOVATION: Does the project employ novel concepts, approaches or methods?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
INVESTIGATOR: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?
ENVIRONMENT: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below).
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the sections on
Federal Citations, below).
ADDITIONAL REVIEW CONSIDERATIONS
Sharing Research Data
Applicants requesting more than $500,000 in direct costs in any year of the
proposed research are expected to include a data sharing plan in their
application. The reasonableness of the data sharing plan or the rationale for
not sharing research data will be assessed by the reviewers. However,
reviewers will not factor the proposed data sharing plan into the
determination of scientific merit or priority score. (See Federal Citation
below.)
BUDGET: The reasonableness of the proposed budget and the requested period
of support in relation to the proposed research.
AWARD CRITERIA
Applications submitted in response to a PA will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
Because the nature and scope of the research proposed will vary, it is
anticipated that the size of each award also will vary. Other things being
equal, cost and program relevance may be considered in making awards. If
several applications are of similarly high scientific and technical merit,
preference for funding may be given to competitive continuation of existing
resources.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent May 1, 2004
New Applications June 1, 2004
Competing Continuations, Supplements, and Revisions July 1, 2004
Scientific Merit Review Oct-Nov, 2004
Advisory Council Review Jan-Feb, 2005
Earliest Anticipated Start Date April 2005
Letter of Intent January 2, 2005
New Applications February 1, 2005
Competing Continuations, Supplements, and Revisions March 1, 2005
Scientific Merit Review June-July, 2005
Advisory Council Review Sept-Oct, 2005
Earliest Anticipated Start Date December 2005
Letter of Intent September 1, 2005
New Applications October 1, 2005
Competing Continuations, Supplements, and Revisions November 1, 2005
Scientific Merit Review Feb-March, 2006
Advisory Council Review May-June, 2006
Earliest Anticipated Start Date July 2006
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45 CFR 46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
SHARING RESEARCH DATA
Starting with the October 1, 2003 receipt date, investigators submitting an
NIH application seeking more than $500,000 or more in direct costs in any
single year are expected to include a plan for data sharing or state why this
is not possible. http://grants.nih.gov/grants/policy/data_sharing
Investigators should seek guidance from their institutions, on issues related
to institutional policies, local IRB rules, as well as local, state and
Federal laws and regulations, including the Privacy Rule. Reviewers will
consider the data sharing plan but will not factor the plan into the
determination of the scientific merit or the priority score.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of
the research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. A
continuing education program in the protection of human participants in
research is available online at: http://cme.nci.nih.gov/
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2)
cited publicly and officially by a Federal agency in support of an action
that has the force and effect of law (i.e., a regulation) may be accessed
through FOIA. It is important for applicants to understand the basic scope
of this amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the Standards for Privacy of Individually Identifiable Health Information ,
the Privacy Rule, on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as covered entities ) must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on Am I a covered
entity? Information on the impact of the HIPAA Privacy Rule on NIH
processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of "Healthy
People 2010," a PHS-led national activity for setting priority areas. This PA
is related to one or more of the priority areas. Potential applicants may
obtain a copy of "Healthy People 2010" at
http://www.health.gov/healthypeople/
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||